Jean-Sébastien Delisle is a Clinician-Scientist at Hôpital Maisonneuve-Rosemont (HMR) and an Associate Professor in the Department of Medicine at Université de Montréal.
After completing his medical and hematology training in 2004 at McGill University, and his PhD in biomedical sciences at the Université de Montréal in 2010, Dr. Delisle focused his research on T-cell biology and human T-cell adoptive therapy. He now leads a research program in T-cell biology and translational T-cell immunotherapy at HMR and is the Medical Director of the Centre of Excellence for Cellular Therapy (CECT), a Good Manufacturing Practice (GMP) cell processing facility.
Dr. Delisle led the development and implementation of several research protocols. These efforts yielded the first adoptive immunotherapy study in Canada to treat or prevent Epstein-Barr virus-related lymphoma, and blood cancer relapse following hematopoietic cell transplantation through the targeting of newly identified transplantation antigens. His current work includes the translation of genetically edited T cells using various approaches. This pipeline is supported by Dr. Delisle’s focus on basic science, which revolve around T-cell priming, differentiation and exhaustion with the goal of improving adoptive immunotherapy using ex vivo expanded T-cell.